AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32619740 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN5A sequencing
Number of subjects: 586
Study 32620006 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) system (electronic alert and standardized care pathway)
Number of subjects: 225
Study 32620116 — intervention group
Group type: EXPERIMENTAL
Intervention: CareWell integrated care model
Number of subjects: 200
Study 32620116 — intervention group
Group type: COMPARATOR
Intervention: Regular care procedures (Control)
Number of subjects: 200
Study 32620161 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (EI) service intensity
Number of subjects: 139
Study 32620161 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver perceptions of environmental support
Number of subjects: 139
Study 32620211 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10mg/kg every two weeks until progression or unacceptable toxicity
Number of subjects: 32
Study 32620404 — intervention group
Group type: EXPERIMENTAL
Intervention: Delphi-derived scale for aesthetic assessment
Number of subjects: 61
Study 32620494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model based on 10 independent variables (SYNTAX score, critical preoperative state, left ventricular ejection fraction, angina at rest, poor mobility, recent potent antiplatelet use, estimated glomerular filtration rate, body mass index, sex, age)
Number of subjects: 7352
Study 32620494 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 7352
Study 32620520 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolisation (TACE) using irinotecan-eluting beads (LifePearl® Microspheres)
Number of subjects: 0
Study 32620536 — intervention group
Group type: EXPERIMENTAL
Intervention: olipudase alfa
Number of subjects: 5
Study 32620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight
Number of subjects: 3719
Study 32620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight
Number of subjects: 3719
Study 32620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 3719
Study 32620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 3719
Study 32620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 3719
Study 32620676 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis subcohort
Number of subjects: 3719
Study 32621083 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly dulaglutide (1.5 mg and 0.75 mg)
Number of subjects: 787
Study 32621250 — intervention group
Group type: EXPERIMENTAL
Intervention: Iatrogenic PTB
Number of subjects: 987
Study 32621250 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous preterm labour (SPL)
Number of subjects: 987
Study 32621250 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm prelabour rupture of membranes (PPROM)
Number of subjects: 987
Study 32621250 — intervention group
Group type: COMPARATOR
Intervention: Generalised Estimating Equations approach
Number of subjects: 987
Study 32621644 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/d
Number of subjects: 57
Study 32621644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 32621959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder depression patients
Number of subjects: 37
Study 32621959 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 37
Study 32622665 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum high sensitivity C-reactive protein (hsCRP)
Number of subjects: 0
Study 32622665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum neutrophil elastase
Number of subjects: 0
Study 32622695 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ADMA concentrations in RA patients
Number of subjects: 164
Study 32622695 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma hArg concentrations in RA patients
Number of subjects: 164
Study 32622695 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of endothelial dysfunction (ED) in RA patients
Number of subjects: 164
Study 32622695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ln-RHI in RA patients
Number of subjects: 164
Study 32622774 — intervention group
Group type: EXPERIMENTAL
Intervention: QC-DeMo (deprescribing module in interprofessional quality circles)
Number of subjects: 0
Study 32622774 — intervention group
Group type: EXPERIMENTAL
Intervention: IDeI (deprescribing-focused medication review)
Number of subjects: 0
Study 32622884 — intervention group
Group type: EXPERIMENTAL
Intervention: Futibatinib 20 mg q.d.
Number of subjects: 86
Study 32622884 — intervention group
Group type: EXPERIMENTAL
Intervention: Futibatinib 8-200 mg t.i.w. or 4-24 mg q.d.
Number of subjects: 86
Study 32623075 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA-negative patients
Number of subjects: 82
Study 32623075 — intervention group
Group type: COMPARATOR
Intervention: ctDNA-positive patients
Number of subjects: 82
Study 32623075 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA positivity
Number of subjects: 82
Study 32623096 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV)
Number of subjects: 261
Study 32623316 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 0
Study 32623316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 0
Study 32623367 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative e-Writing Intervention (NeW-I)
Number of subjects: 72
Study 32623367 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study 32623479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 59
Study 32623724 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ultrasound
Number of subjects: 1025
Study 32623724 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound plus exercise
Number of subjects: 1025
Study 32624004 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised in-hospital physical activity program
Number of subjects: 120
Study 32624004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 120
Study 32624195 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir monotherapy
Number of subjects: 0
Study 32624280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT) with 400 mg testosterone cypionate intramuscularly every 28 days
Number of subjects: 59
Study 32624280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT)
Number of subjects: 59
Study 32624280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar androgen therapy (BAT) followed by AR-targeted therapy rechallenge
Number of subjects: 59
Study 32624458 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for low CFC lesions
Number of subjects: 1397
Study 32624458 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) for normal CFC lesions
Number of subjects: 1397
Study 32624458 — intervention group
Group type: COMPARATOR
Intervention: Deferred PCI for lesions with FFR ≤0.8 and normal CFC
Number of subjects: 1397
Study 32625123 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise intervention (150 min per week)
Number of subjects: 314
Study 32625123 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 314
Study 32625143 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMPLE-PE intervention (specific details not provided)
Number of subjects: 0
Study 32625239 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolically healthy obesity (MHO)
Number of subjects: 2076
Study 32625239 — intervention group
Group type: COMPARATOR
Intervention: Metabolically unhealthy individuals (MUNO, MUO)
Number of subjects: 2076
Study 32627114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB) treatment at the graft vein junction after successful percutaneous thrombectomy.
Number of subjects: 20
Study 32627589 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media advertising (Facebook)
Number of subjects: 0
Study 32627589 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted mailing
Number of subjects: 0
Study 32627589 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person solicitation of clinic patients
Number of subjects: 0
Study 32627589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of recruitment strategies
Number of subjects: 0
Study 32627860 — intervention group
Group type: COMPARATOR
Intervention: Resilience training (combined theoretical foundation including mindfulness and cognitive-behavioral therapy)
Number of subjects: 6892
Study 32628342 — intervention group
Group type: EXPERIMENTAL
Intervention: Current chronic graft-vs-host disease
Number of subjects: 279
Study 32628342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue and physical function
Number of subjects: 279
Study 32628342 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress and social support
Number of subjects: 279
Study 32628342 — intervention group
Group type: EXPERIMENTAL
Intervention: Final model including all factors
Number of subjects: 279
Study 32628583 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel given every 3 weeks for 4 cycles plus subcutaneous trastuzumab
Number of subjects: 60
Study 32628583 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and subcutaneous trastuzumab
Number of subjects: 60
Study 32628583 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab
Number of subjects: 60
Study 32628945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette Purchase Task (CPT)
Number of subjects: 745
Study 32628945 — intervention group
Group type: EXPERIMENTAL
Intervention: Heaviness of Smoking Index (HSI)
Number of subjects: 745
Study 32628945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fagerström Test for Nicotine Dependence (FTND)
Number of subjects: 745
Study 32628945 — intervention group
Group type: EXPERIMENTAL
Intervention: FTND total scores minus items 1 and 4
Number of subjects: 745
Study 32629123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean participants with NAFLD
Number of subjects: 3386
Study 32629123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean Asian participants with NAFLD
Number of subjects: 3386
Study 32629127 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Liver Fibrosis Score
Number of subjects: 0
Study 32629625 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care clinical ultrasound classroom (AECAP)
Number of subjects: 20
Study 32629625 — intervention group
Group type: COMPARATOR
Intervention: Control group of family physicians with similar characteristics
Number of subjects: 20
Study 32629749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography
Number of subjects: 0
Study 32629749 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0
Study 32629749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography and MRI
Number of subjects: 0
Study 32631100 — intervention group
Group type: EXPERIMENTAL
Intervention: Convolutional Neural Network (CNN) classification of AF image grids
Number of subjects: 35
Study 32631100 — intervention group
Group type: COMPARATOR
Intervention: Support vector machines, traditional linear discriminant, and k-nearest neighbor analyses
Number of subjects: 35
Study 32631100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient-weighted class activation mapping applied to CNN
Number of subjects: 35
Study 32631269 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 3172
Study 32631269 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate GWG
Number of subjects: 3172
Study 32631269 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 3172
Study 32631269 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive GWG
Number of subjects: 3172
Study 32631293 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP patients at 4 months post-surgery
Number of subjects: 1761
Study 32631293 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP patients at 1 year post-surgery
Number of subjects: 1761
Study 32631293 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP patients at 2 years post-surgery
Number of subjects: 1761
Study 32631293 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP patients with mesh repair at 4 months post-surgery
Number of subjects: 1761
Study 32631293 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP patients with non-mesh repair at 4 months post-surgery
Number of subjects: 1761
Study 32631293 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients at 2 years post-surgery
Number of subjects: 1761
Study 32631293 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP patients
Number of subjects: 1761
Study 32631293 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 1761
Study 32631491 — intervention group
Group type: EXPERIMENTAL
Intervention: UGN-101 (mitomycin 4 mg per mL; maximum 60 mg per instillation) administered via retrograde catheter to the renal pelvis and calyces, with six instillations once weekly.
Number of subjects: 74
Study 32631491 — intervention group
Group type: EXPERIMENTAL
Intervention: UGN-101
Number of subjects: 74
Study 32631655 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 10
Study 32631655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation
Number of subjects: 10
Study 32631655 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation with nivolumab
Number of subjects: 10
Study 32631787 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with Aflibercept (Arm A, starting dose 1100 mg/m²)
Number of subjects: 38
Study 32631787 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with Aflibercept (recommended dose for phase II trials established at 1300 mg/m²)
Number of subjects: 38
Study 32631787 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study 32631788 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab 6 mg/kg every 2 weeks until progression or unacceptable toxicity
Number of subjects: 41
Study 32632095 — intervention group
Group type: EXPERIMENTAL
Intervention: Descartes-08 (CD8+ anti-BCMA mRNA CAR T cells)
Number of subjects: 0
Study 32632956 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen plus ultraviolet A (PUVA) light treatment
Number of subjects: 1369
Study 32632956 — intervention group
Group type: COMPARATOR
Intervention: Intralesional interferon-α (IFN-α)
Number of subjects: 1369
Study 32632956 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 1369
Study 32632956 — intervention group
Group type: COMPARATOR
Intervention: Bexarotene plus PUVA
Number of subjects: 1369
Study 32632956 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous IFN-α with acitretin or PUVA
Number of subjects: 1369
Study 32632956 — intervention group
Group type: COMPARATOR
Intervention: PUVA maintenance treatment
Number of subjects: 1369
Study 32633094 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish Orthostatic Hypotension Questionnaire (OHQ)
Number of subjects: 29
Study 32633563 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of talimogene laherparepvec with atezolizumab
Number of subjects: 0
Study 32633861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Number of subjects: 1631
Study 32634066 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 293
Study 32634122 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of autoantibodies in ICL patients
Number of subjects: 72
Study 32634122 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of IgM and IgG anti-CD4+ cell antibodies
Number of subjects: 72
Study 32634122 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical complement activation on CD4+ T cells
Number of subjects: 72
Study 32634234 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 400 mg daily + ruxolitinib 20 mg twice daily
Number of subjects: 50
Study 32634238 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen of alemtuzumab, hydroxyurea, fludarabine, melphalan, and thiotepa with a single-unit umbilical cord blood graft.
Number of subjects: 44
Study 32634238 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning regimen with single-unit umbilical cord blood graft.
Number of subjects: 44
Study 32634238 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of cord donor leukocyte infusion (cDLI) posttransplant.
Number of subjects: 44
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilator-associated pneumonia (VAP)
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol abuse
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug abuse
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic trauma
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory failure episodes
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of mechanical ventilation
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU length of stay (LOS)
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological outcome
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (hazard ratio)
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest trauma (hazard ratio)
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine-receptor antagonist intake (hazard ratio)
Number of subjects: 962
Study 32634435 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (hazard ratio)
Number of subjects: 962
Study 32634461 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking football program
Number of subjects: 31
Study 32634610 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 160 mg
Number of subjects: 0
Study 32634611 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1) 3.6 mg/kg every 3 weeks (intravenously) until unacceptable toxicity, withdrawal of consent, or disease progression
Number of subjects: 398
Study 32634812 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbol Digit Modalities Test (SDMT)
Number of subjects: 81
Study 32634812 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological and semantic verbal fluency
Number of subjects: 81
Study 32634812 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Error of Measurement (SEM) and Minimum Detectable Change (MDC)
Number of subjects: 81
Study 32634812 — intervention group
Group type: COMPARATOR
Intervention: Cognitive modification assessment
Number of subjects: 81
Study 32635158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence sampling of the root canal space prior to obturation
Number of subjects: 65
Study 32635224 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-related gene (IRG) expression analysis
Number of subjects: 71
Study 32635680 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0
Study 32636288 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic pathway for autism assessment, compliant with NICE guidelines, aimed to be completed within 13 weeks.
Number of subjects: 0
Study 32636632 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (FUL)
Number of subjects: 168
Study 32636632 — intervention group
Group type: COMPARATOR
Intervention: Everolimus plus Exemestane (EVE-EXE)
Number of subjects: 168
Study 32636771 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment for 1 year
Number of subjects: 301
Study 32636943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure hyperbaric oxygen therapy (HBOT)
Number of subjects: 49
Study 32636943 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise program (PEG)
Number of subjects: 49
Study 32637360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus Docetaxel and Cisplatin regimen
Number of subjects: 0
Study 32637723 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (predominantly Roux-en-Y gastric bypass)
Number of subjects: 50
Study 32637723 — intervention group
Group type: COMPARATOR
Intervention: Intensive non-surgical treatment starting with an eight-week low-calorie diet
Number of subjects: 50
Study 32637895 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 100
Study 32637901 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard BI (in-person problem-solving skills training)
Number of subjects: 621
Study 32637901 — intervention group
Group type: COMPARATOR
Intervention: Web-based BI (mobile device problem-solving skills training)
Number of subjects: 621
Study 32637899 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy (NCRT)
Number of subjects: 0
Study 32637899 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NCT)
Number of subjects: 0
Study 32637899 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 32638098 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FAZA PET/CT
Number of subjects: 20
Study 32638211 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-panel mutation testing
Number of subjects: 131
Study 32638247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D/calcium deficiency assessment before bariatric-metabolic surgery
Number of subjects: 52
Study 32638247 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of 25(OH)D threshold for maximal suppression of parathyroid hormone (PTH)
Number of subjects: 52
Study 32638703 — intervention group
Group type: EXPERIMENTAL
Intervention: Toi Même app for self-monitoring mood and behavioral parameters
Number of subjects: 93
Study 32638703 — intervention group
Group type: EXPERIMENTAL
Intervention: Toi Même app
Number of subjects: 93